Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarclisa
Pharma
Sanofi's subQ version of Sarclisa measures up to its IV version
A phase 3 trial of Sanofi's subcutaneous version of Sarclisa has met its primary co-endpoints, showing non-inferiority to intravenous Sarclisa.
Kevin Dunleavy
Jan 9, 2025 11:14am
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
Sep 27, 2024 3:59pm
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
ASCO: Sanofi's Sarclisa looks to step out of J&J's myeloma shadow
Jun 3, 2024 4:00pm
ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma
Dec 12, 2023 12:00pm
Sanofi targets first-line myeloma as Sarclisa delivers trial win
Dec 7, 2023 11:26am
